In addition, breast cancer survivors taking aromatase inhibitors (AIs) might also be vulnerable to this effect given that AI’s are associated with acceleration of bone loss and an increased risk of osteoporotic fractures. This evidence concerns the gene CYP19A1 and breast cancer.